Turn Therapeutics (TTRX) director gets 71,666 stock options at $5.75 strike

Rhea-AI Filing Summary

Turn Therapeutics director Martin William Dewhurst received a grant of stock options covering 71,666 shares of Common Stock at an exercise price of $5.75 per share. The options vest in twelve equal monthly installments beginning on June 30, 2026 and expire on June 4, 2036.

Following this award, he holds 71,666 stock options directly, all tied to continued employment and the terms of the 2025 Omnibus Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dewhurst Martin William

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	71,666	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 71,666 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 71,666 options Exercise price: $5.75 per share Expiration date: June 4, 2036 +2 more

5 metrics

Options granted 71,666 options Grant to director on June 4, 2026

Exercise price $5.75 per share Stock option strike price

Expiration date June 4, 2036 Option term end

Vesting schedule 12 monthly installments Beginning June 30, 2026

Post-transaction options held 71,666 options Total derivative holdings after grant

Key Terms

Stock option, exercise price, vesting, Omnibus Incentive Plan, +1 more

5 terms

Stock option financial

"Stock option (right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "5.7500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option will vest in twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Omnibus Incentive Plan financial

"Issuer's 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/08/2026 - 05:32 PM Accepted by SEC EDGAR 06/08/2026 - 05:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dewhurst Martin William

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.75	06/04/2026		A		71,666		(1)	06/04/2036	Common Stock	71,666	$0	71,666	D

Explanation of Responses:

1. The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

	/s/ Zuraiz Chaudhary, attorney-in-fact for Martin William Dewhurst	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Turn Therapeutics (TTRX) report for Martin William Dewhurst?

Turn Therapeutics reported that director Martin William Dewhurst received a grant of 71,666 stock options. These options give him the right to buy Common Stock at $5.75 per share, subject to vesting and the company’s 2025 Omnibus Incentive Plan.

How many Turn Therapeutics (TTRX) stock options were granted to director Dewhurst?

Dewhurst was granted 71,666 stock options for Turn Therapeutics Common Stock. Each option allows purchase at an exercise price of $5.75 per share, with vesting spread over twelve monthly installments starting in June 2026.

When do Martin Dewhurst’s Turn Therapeutics (TTRX) stock options vest and expire?

The options vest in twelve equal monthly installments starting on June 30, 2026. All options expire on June 4, 2036, meaning they must be exercised before that date, assuming vesting and continued employment conditions are met.

What is the exercise price of the new Turn Therapeutics (TTRX) stock options granted?

The newly granted stock options have an exercise price of $5.75 per share. This is the price Dewhurst must pay to convert each vested option into one share of Turn Therapeutics Common Stock within the option term.

How many Turn Therapeutics (TTRX) options does Dewhurst hold after this Form 4 transaction?

After this transaction, Dewhurst holds 71,666 stock options directly. All these options relate to the new grant reported and are subject to the vesting schedule and conditions in the 2025 Omnibus Incentive Plan.